Femasys Launches First Commercial Use of FemaSeed Complete in OB/GYN Setting
Event summary
- Femasys Inc. announced the first revenue-generating commercial use of FemaSeed Complete in the OB/GYN setting on May 5, 2026.
- The procedure combines FemaSeed intratubal insemination with FemSperm sperm preparation, enabling in-office fertility treatment.
- Dr. Finazzo of Downriver OBGYN in Trenton, MI, performed the first procedure, marking a shift in fertility care to primary OB/GYN practices.
- Femasys aims to address the infertility treatment gap, with fewer than 1% of affected women receiving care at specialized fertility centers.
- FemaSeed Complete is designed to streamline procedural workflow and reduce costs compared to traditional IVF.
The big picture
Femasys is driving a strategic shift in fertility care by enabling OB/GYNs to offer first-line treatments, addressing a significant access gap. With U.S. fertility rates at record lows, this model could expand the total addressable market for fertility services. The success of this approach hinges on cost efficiency and earlier intervention, potentially disrupting the traditional IVF-dominated landscape.
What we're watching
- Market Adoption
- How quickly OB/GYN practices will adopt FemaSeed Complete as a first-line fertility treatment.
- Regulatory Approvals
- Whether Femasys can secure additional regulatory approvals for its fertility and birth control products.
- Competitive Response
- How traditional fertility clinics and IVF providers will react to this shift in care delivery.